Pharmarise Holdings Corporation (2796.T)
JPY 563.0
(-2.26%)
JPY 563.0
(-2.26%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 2.71 Billion | 2.52 Billion | 713 Million | 1.94 Billion | 1.57 Billion | 895 Million |
| Net Income | -351 Million | 1.04 Billion | 1.32 Billion | 1.2 Billion | 819 Million | 400 Million |
| Depreciation & Amortization | 1.17 Billion | 1.22 Billion | 1.3 Billion | 1.34 Billion | 1.22 Billion | 1.22 Billion |
| Deferred income taxes | - | - | - | - | -270 Million | -562 Million |
| Stock-based compensation | - | - | - | - | 37 Million | 40 Million |
| Change in working capital | 1.78 Billion | 513 Million | -1.46 Billion | -139 Million | -612 Million | -258 Million |
| Other non-cash items | 858 Million | -266 Million | -452 Million | -462 Million | 370 Million | 52 Million |
| Investing Cash Flow | -3.12 Billion | -703 Million | -292 Million | -1.07 Billion | -734 Million | -501 Million |
| Investments in PPE | -619 Million | -542 Million | -466 Million | -552 Million | -457 Million | -458 Million |
| Acquisitions | -2.37 Billion | -180 Million | 2 Million | -116 Million | -468 Million | -197 Million |
| Investment purchases | - | - | -2 Million | -2 Million | 26 Million | -10 Million |
| Sales/Maturities of investments | 43 Million | - | 383 Million | 12 Million | 10 Million | 163 Million |
| Other Investing Activities | -175 Million | 19 Million | -209 Million | -418 Million | 155 Million | 1 Million |
| Financing Cash Flow | 2.77 Billion | -1.07 Billion | -1.03 Billion | -728 Million | -766 Million | 354 Million |
| Debt repayment | -3.31 Billion | -2.41 Billion | -2.63 Billion | -2.85 Billion | -2.82 Billion | -3.11 Billion |
| Dividends payments | -127 Million | -131 Million | -131 Million | -129 Million | -129 Million | -125 Million |
| Common Stock Repurchased | -340 Million | - | -2 Million | -36 Million | -173 Million | 3.49 Billion |
| Common Stock Issuance | - | - | 1.73 Billion | 2.19 Billion | 2.36 Billion | 103 Million |
| Other Financing Activities | -73 Million | 1.47 Billion | -2 Million | 95 Million | -2 Million | -2 Million |
| Accounts receivables | 1.48 Billion | 482 Million | -1.31 Billion | 365 Million | 373 Million | 228 Million |
| Accounts payables | 137 Million | 13 Million | -500 Million | -582 Million | -258 Million | -506 Million |
| Inventory | -26 Million | 68 Million | 286 Million | 56 Million | -342 Million | 12 Million |
| Other working capital | 193 Million | -50 Million | 68 Million | 22 Million | -385 Million | 8 Million |
| Cash at beginning of period | 4.74 Billion | 3.99 Billion | 4.6 Billion | 4.46 Billion | 4.39 Billion | 3.64 Billion |
| Cash at end of period | 7.1 Billion | 4.73 Billion | 3.99 Billion | 4.6 Billion | 4.46 Billion | 4.39 Billion |
| Capital Expenditure | -619 Million | -542 Million | -466 Million | -552 Million | -457 Million | -458 Million |
| Effect of forex changes on cash | - | -2 Million | - | -1 Million | -1 Million | 2 Million |
| Net cash flow / Change in cash | 2.35 Billion | 743 Million | -613 Million | 140 Million | 71 Million | 750 Million |
| Free Cash Flow | 2.09 Billion | 1.97 Billion | 247 Million | 1.39 Billion | 1.11 Billion | 437 Million |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -131 Million | -351 Million | -528 Million | -96 Million | 150 Million | 123 Million |
| Depreciation & Amortization | - | 1.17 Billion | 299.5 Million | - | 292 Million | 279 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | 1.78 Billion | 417.5 Million | - | - | - |
| Other non-cash items | 131 Million | 858 Million | 528 Million | 96 Million | -150 Million | -123 Million |
| Investing Cash Flow | - | -3.12 Billion | -1.28 Billion | - | - | - |
| Investments in PPE | - | -619 Million | -77.5 Million | - | - | - |
| Acquisitions | - | -2.37 Billion | -1.15 Billion | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | 43 Million | - | - | - | - |
| Other Investing Activities | - | -175 Million | -51.5 Million | - | - | - |
| Financing Cash Flow | - | 2.77 Billion | 1.94 Billion | - | - | - |
| Debt repayment | - | -3.31 Billion | - | - | - | - |
| Dividends payments | - | -127 Million | - | - | - | - |
| Common Stock Repurchased | - | -340 Million | -170 Million | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | -73 Million | 2.11 Billion | - | - | - |
| Accounts receivables | - | 1.48 Billion | 288.5 Million | - | - | - |
| Accounts payables | - | 137 Million | - | - | - | - |
| Inventory | - | -26 Million | 72.5 Million | - | - | - |
| Other working capital | - | 193 Million | 56.5 Million | - | - | - |
| Cash at beginning of period | - | 4.74 Billion | - | - | 4.87 Billion | 4.74 Billion |
| Cash at end of period | - | 7.1 Billion | 1.08 Billion | - | 4.92 Billion | 4.87 Billion |
| Capital Expenditure | - | -619 Million | -77.5 Million | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | 2.35 Billion | 1.08 Billion | - | 46 Million | 135 Million |
| Free Cash Flow | - | 2.09 Billion | 349.5 Million | - | 584 Million | 558 Million |
ATRX
ARKO
0703
FHTX
8923
EXPO